Question 1

Berapa harga saham Biogen hari ini?

Accepted Answer

Harga semasa Biogen ialah 130.50 USD — ia telah meningkat sebanyak 3.93% dalam 24 jam yang lepas. Lihat prestasi harga saham Biogen dengan lebih teliti pada grafik lanjutan.

Question 2

Apakah simbol saham Biogen?

Accepted Answer

Bergantung pada bursa, simbol saham mungkin berbeza. Sebagai contoh, di bursa NASDAQ, saham Biogen diniagakan dengan simbol BIIB.

Question 3

Adakah harga saham BIIB sedang naik?

Accepted Answer

Saham BIIB telah meningkat sebanyak 2.52% dalam minggu lepas, telah meningkat sebanyak 0.59% dalam bulan lepas, dan telah menurun sebanyak -43.71% dalam tahun lepas. Lihat lebih banyak data pada grafik BIIB.

Question 4

Apakah cadangan penganalisis untuk BIIB?

Accepted Answer

Setakat 01 Jul 2025, daripada 19 cadangan penganalisis, majoriti memberi penarafan BIIB sebagai hold.

Question 5

Apakah nilai pasaran BIIB?

Accepted Answer

Setakat hari ini, BIIB mempunyai kapitalisasi pasaran sebanyak 18.51B USD. Jelajahi senarai saham kami yang diatur mengikut kapitalisasi pasaran untuk membandingkan BIIB dengan saham lain.

Question 6

Adakah BIIB mengeluarkan laporan kewangan?

Accepted Answer

Ya, anda boleh menjejaki kewangan BIIB dalam laporan tahunan dan suku tahunan di Profit.com.

Question 7

Bila tarikh laporan pendapatan seterusnya BIIB?

Accepted Answer

BIIB akan mengeluarkan laporan pendapatan seterusnya pada 30 Jul 2025. Jejak acara yang akan datang dengan Kalendar Pendapatan kami.

Question 8

Berapa pendapatan BIIB untuk suku tahunan lepas?

Accepted Answer

BIIB melaporkan pendapatan sebanyak $3.44 setiap saham untuk suku tahunan lepas, lebih tinggi daripada anggaran $3.3639 setiap saham, menghasilkan kejutan 2.26%. Pendapatan yang dianggarkan untuk suku tahunan akan datang adalah $2.9648 setiap saham. Lihat butiran lanjut tentang pendapatan BIIB di Profit.com.

Question 9

Berapa hasil BIIB untuk suku tahunan lepas?

Accepted Answer

Hasil BIIB untuk suku tahunan lepas ialah 2.43B USD, lebih tinggi daripada anggaran 2.28B USD. Hasil yang dianggarkan untuk suku tahunan akan datang ialah 2.32B USD. Lihat lebih banyak statistik dalam laporan kewangan BIIB di Profit.com.

Question 10

Berapa Pendapatan Bersih BIIB untuk suku tahunan lepas?

Accepted Answer

Pendapatan bersih BIIB untuk suku tahunan lepas adalah 240.5M USD, manakala suku tahunan sebelumnya menunjukkan pendapatan bersih sebanyak 266.7M USD, yang mencatatkan perubahan sebanyak -9.82%. Lihat lebih banyak statistik dalam laporan kewangan BIIB di Profit.com.

Question 11

Adakah BIIB membayar dividen?

Accepted Answer

Tidak, BIIB tidak membayar sebarang dividen kepada pemegang sahamnya. Tetapi anda boleh meneroka senarai stok berdividen tinggi di Profit.com.

Question 12

Berapa ramai pekerja yang ada di BIIB?

Accepted Answer

Sehingga 01 Jul 2025, BIIB menggaji kira-kira 7605 pekerja. Lihat jika BIIB berada dalam senarai majikan terbesar kami.

Question 13

Apakah EBITDA BIIB?

Accepted Answer

EBITDA, yang mengukur prestasi operasi syarikat, mencerminkan peningkatan kecekapan. EBITDA BIIB ialah 3.08B USD, dengan margin EBITDA semasa sebanyak 15.07%. Lihat lebih banyak statistik dalam laporan kewangan BIIB di Profit.com.

Question 14

Bagaimana untuk membeli saham BIIB?

Accepted Answer

Seperti saham lain, saham BIIB diperdagangkan di bursa saham seperti NASDAQ. Cara paling mudah untuk membelinya adalah melalui broker saham dalam talian. Buka akaun, ikuti prosedur broker, dan mula berdagang. Sebagai alternatif, anda boleh berlatih berdagang saham Tesla di Profit.com dalam Playtrade Tournaments atau pilih broker yang disyorkan untuk berdagang terus.

Question 15

Patutkah saya melabur dalam saham BIIB?

Accepted Answer

Melabur dalam saham memerlukan penyelidikan yang teliti, termasuk menganalisis kewangan syarikat, berita berkaitan, dan analisis teknikal. Pada masa ini, cadangan penganalisis teknikal Tesla menunjukkan penarafan hold.

Sebelum melabur dalam BIIB, pertimbangkan untuk melanggan Profit PRO di mana anda boleh berlatih berdagang dalam Playtrade Tournaments, mengakses pandangan pasaran harian yang digerakkan oleh AI, menyalin Watchlists yang dipilih dengan teliti, dan mengikuti Portfolia Bilionaire.

Biogen Inc

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy

Sage Therapeutics rejects Biogen bid, starts strategic review

Sage sues Biogen in wake of $469M buyout offer: report

Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment

Drugmaker Biogen boosts profit outlook on ‘momentum’ for new drugs

Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction

Sage Therapeutics’ stock dives as failed trial hits Biogen collaboration

IGM Biosciences up 40% following Biogen HI-Bio buy

Biogen inks $1.8B deal to acquire immune drug developer HI-Bio

Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments

Biogen drops controversial Alzheimer’s drug

China approves Alzheimer's treatment Leqembi by Eisai and Biogen https://t.co/L6fn9ObDxr https://t.co/bM0VWP0qdN

Biogen quarterly results top estimates despite complex launch of new Alzheimer’s treatment

Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake

Reata shareholders clear buyout deal with Biogen

Reata Pharmaceuticals climbs as HSR waiting period for sale to Biogen expired

Biogen in $1.5B unsecured loan facility for Reata acquisition

Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering

Larimar, Design higher as they benefit from Biogen deal for Reata

Biogen agrees to buy Reata Pharmaceuticals in deal valued at $7.3B

Biogen to slash 1,000 jobs as it looks to save $700 million

Biogen to cut 1,000 jobs to save costs as company prepares for Leqembi launch

Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more

US FDA grants standard approval of Eisai/Biogen Alzheimer's drug https://t.co/dPTZVWV7nY https://t.co/tJhiKLMMhK

Movers & Shakers: Biogen stock climbs on drug approval recommendation, Oracle shares rise ahead of earnings, and other stocks on the move

FDA advisers vote in favor of Biogen and Eisai’s collaborative Alzheimer’s treatment

Eisai-Biogen Alzheimer's drug data confirms benefits, FDA staff says https://t.co/B8zM9OuUMN https://t.co/kBnCzNJITx

Eisai-Biogen Alzheimer's drug data confirms benefits, FDA staff says https://t.co/rT7SXVtPut https://t.co/xEscFEsucz

Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds https://t.co/PPwucQj4cX https://t.co/jc4T3ZHDl7

Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds https://t.co/FVizSAXwgQ https://t.co/ZsPKuBM8R7

Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds https://t.co/4EKjVSspfk https://t.co/nBrtuI75sw

Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says

Millions of Americans are expected to test for Alzheimer’s disease – some with at-home DNA test kits, others at labs — as new drugs for early Alzheimer’s, from partners Eisai and Biogen and Eli Lilly, usher in sweeping changes in treatment https://t.co/D1Ny08kJSN https://t.co/JgfEBUurn0

US FDA advisers to weigh full approval for Eisai-Biogen's Alzheimer's drug https://t.co/sx3nKxLoYv https://t.co/wxL63AqsHx

Pfizer, Biogen among hundreds of US drugmakers calling for abortion pill ruling reversal https://t.co/nKnJKMfnHr https://t.co/yjm0WBw4GW

US FDA advisers to weigh full approval for Eisai-Biogen's Alzheimer's drug https://t.co/MysxC06M8V https://t.co/jxvX3Sw1y5

Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab https://t.co/eRoU2JxunD https://t.co/VAzT0W4iCb

Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab https://t.co/Ym1X51nVBV https://t.co/9NTKMbzI1r

Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab https://t.co/Bysx8mHeA4 https://t.co/bpjbjrlj87

Eisai, Biogen say Alzheimer's drug Lecanemab getting priority review in China https://t.co/8L0q1rOVxR https://t.co/L0KELgN969

Biogen CEO bets on Alzheimer's drug, pipeline to return to growth https://t.co/Fyg7ni9vv2 https://t.co/nPYonFlBKc

Biogen CEO bets on Alzheimer's drug, pipeline to return to growth https://t.co/GORyQxXcGd https://t.co/j4pNpDagY6

Biogen sees modest 2023 revenue from Alzheimer's disease drug https://t.co/XL1BwDKqTw https://t.co/uqdedtLHPw

Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen https://t.co/Wh8Tcs5azk https://t.co/5J5pZ9use9

Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen https://t.co/kTrEVHePch https://t.co/8oM6hrjRR5

Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen https://t.co/wRxWzvIfq7 https://t.co/GrwduIAOfK

EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen https://t.co/JiSVeEebG6 https://t.co/5R3pEbciD4

EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen https://t.co/15Wmhb3k6S https://t.co/Slfhelg0Bd

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead https://t.co/8t1jxrKT4a https://t.co/k2Rqhi2hri

Soalan Lazim